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background: Though studies support the cost-effectiveness of TAVR from a societal perspective, the impact of costs on the viability of TAVR 
programs from the hospital’s perspective is not fully understood. Reducing length of stay (LoS) is feasible and safe in selected patients, but the 
impact of this strategy on hospital costs has not been formally evaluated.
Methods: We developed a decision analytic model using detailed cost data from a cohort of 79 patients and outcome data from published 
registries. In the base case scenario, patients without a complication or requiring only a pacemaker remained in hospital for a total of 8 days, 
including two days in the CCU. In sensitivity analyses, these same patients were eligible for reduced LoS scenarios (Table 1).
results:  Individual Patient Level: Without complications, the median total cost of hospitalization was projected to be $81,644 for an 8-day LoS. 
There was a curvilinear relationship between LoS and both direct and total costs (Figure 1) with a difference of $15,221 from 8 to 2 days.
TAVR Program Level: Compared to baseline, Early Discharge resulted in an average savings of $7,929/patient across the entire program, whereas 3M 
Discharge resulted in $10,068 saved per patient.
conclusion: Selective early discharge planning can result in meaningful cost savings at a program level. Early discharge for TAVR patients shows 
promise as part of a global approach to TAVR program cost reduction. However, country-specific nuances in reimbursement must also be considered.
 
